Please login to the form below

Not currently logged in
Email:
Password:

lubiprostone

This page shows the latest lubiprostone news and features for those working in and with pharma, biotech and healthcare.

Mallinckrodt pays $1.2bn for Sucampo Pharma

Mallinckrodt pays $1.2bn for Sucampo Pharma

Mallinckrodt is paying $18 per share for Sucampo and will also assume the company’s $360m debt under the terms of the deal, adding Amitizia (lubiprostone), glaucoma treatment Rescula (unoprostone isopropyl)

Latest news

  • Lilly’s Efient and Sucampo's Amitiza win NICE backing Lilly’s Efient and Sucampo's Amitiza win NICE backing

    NICE, which provides healthcare recommendations to the NHS, issued new guidance on the use of Sucampo Pharma Europe's Amitiza (lubiprostone) for adults with chronic idiopathic constipation and updated its view

  • NICE backs constipation treatment NICE backs constipation treatment

    Sucampo’s Amitiza set for NHS use in England and Wales.  . Sucampo's constipation treatment Amitiza (lubiprostone) should be available on the NHS, according to new healthcare guidance. ... For many of the patients who are refractory to standard

  • AZ drug for opioid constipation starts FDA review AZ drug for opioid constipation starts FDA review

    up to compete with Sucampo and Takeda's twice-daily Amitiza (lubiprostone).

  • An unexpected turn

    Lubiprostone. Amitiza (Takeda Pharmaceuticals). Irritable Bowel Syndrome. US. Mycophenolate mofetil (Cellcept; Roche) is an immunosupressant commonly used for treating and preventing transplant rejection.

  • IBS drug approved in the US

    The drug (lubiprostone), which was developed as part of a joint deal between Sucampo and Takeda Pharmaceuticals North America, can now be prescribed to women over the age of 18 for

More from news
Approximately 1 fully matching, plus 6 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Six Degrees Medical Consulting

For over a decade, our medical communication services have helped pharmaceutical companies optimize their brand, disease and corporate objectives. Building...

Latest intelligence

Empowered patients: shaking the foundations of healthcare
Precision medicine represents a new paradigm in healthcare.This new approach to treating and preventing disease views the patient holistically, analysing their genes, environment and lifestyle, and using this information to...
A uniquely English genomic medicine service
The UK National Health Service is developing one standardised approach to embedding precision medicine across the whole of England. Blue Latitude Health speaks to Dr Tom Fowler, Deputy Chief Scientist...
Blended Intelligence
Data is the most valued commodity of the modern world. For P&P it's all about the application....

Infographics